EUCTR2010-019790-15-IT进行中（未招募）不适用
Open-label, Phase II Clinical Trial of Aplidin (Plitidepsin) in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia (Post-PV/ET) Myelofibrosis - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- PHARMA MAR
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Diagnosis of PMF or post-ET/PV MF as per revised World Health Organization (WHO) criteria (Appendix 3). 2)High-risk or intermediate-2 risk MF as defined by the International Prognostic Scoring System (IPSS) (Appendix 4); or intermediate-I risk MF associated with symptomatic splenomegaly/hepatomegaly and/or unresponsive to available therapy. 3)At least 18 years of age, with life expectancy of >/=12 weeks. 4)Able to provide informed consent and being willing to sign an informed consent form (ICF). 5)Eastern Cooperative Oncology Group (ECOG) performance status /= 1.0 x 10^9/L. d)Platelet count >/= 25 x 10^9/L. e)Left ventricular ejection fraction (LVEF) within normal limits. f)Creatine phosphokinase (CPK) /= 40 mL/min.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Previous treatment with plitidepsin. 2.Any of the following therapies within two weeks prior to initiation of study drug: a)chemotherapy (e.g., hydroxyurea), b)immunomodulatory drug therapy (e.g., thalidomide), c)immunosuppressive therapy, d)corticosteroids >10 mg/day prednisone or equivalent, or e)erythropoietin. 3.Incomplete recovery from major surgery within four weeks of study entry. 4.Radiation therapy within four weeks of study entry. 5.Women of childbearing potential, unless surgically sterile for at least three months (i.e., hysterectomy), or postmenopausal for at least 12 months (follicle-stimulating hormone, FSH > 30 U/mL), or unless they agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) throughout the treatment period and for six months after discontinuation of the treatment. Permitted methods for preventing pregnancy must be communicated to the study patients and their understanding has to be confirmed. 6. Men who partner with a woman of childbearing potential, unless they agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) throughout the treatment period and for six months after discontinuation of the treatment. Permitted methods for preventing pregnancy must be communicated to the study subjects and their understanding has to be confirmed. 7.Women who are pregnant or are currently breastfeeding. 8.Myopathy grade > 2 or any clinical situation that causes significant and persistent elevation of CPK (> 2.5 x ULN in two different determinations performed one week apart). 9.Known positive status for human immunodeficiency virus (HIV). 10.Active hepatitis B or C virus (HBV or HCV) infection and/or significant non-neoplastic liver disease (i.e. cirrhosis). 11.Diagnosis of another invasive malignancy unless free of disease for at least three years following therapy with curative intent. Patients with early-stage basal cell or squamous cell skin cancer, cervical intraepithelial neoplasia, cervical carcinoma in situ, or superficial bladder cancer, may be eligible to participate at the Investigator`s discretion. 12.Any acute active infection. 13.Serious concomitant systemic disorders that would compromise the safety of the patient or limit the patient’s ability to complete or comply with the study, including: a)Uncontrolled medical illness that the Investigator feels will compromise the patient’s tolerance to the study medication. b)Uncontrolled or unstable angina, myocardial infarction, cerebrovascular accident, valvular heart disease or congestive heart failure (New York Heart Association Classification 3 or 4), within 12 months prior to initiation of study drug. c)Pulmonary embolism within three months prior to initiation of study drug. d)Uncontrolled arterial hypertension (>/= 160/110 mmHg) despite optimal medical therapy. e)Previous treatment with doxorubicin at cumulative doses >/= 450 mg/m2. f)Symptomatic arrhythmia (excluding anemia-related sinusal tachycardia grade 450 msec for men or >470 msec for women at pre-study screening, unless attributable to pre-existing bundle branch block. 14.Known hypersensitivity to the study drug or any of its formulation components (e.g., Cremophor). 15.Treatment with any investigational product in the 30 days before inclusion in the study.
研究者
相似试验
已完成
2 期
Clinical Trial of Aplidin® in Patients With Primary MyelofibrosisMyelofibrosisNCT01149681PharmaMar12
已完成
2 期
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple MyelomaMultiple MyelomaNCT00229203PharmaMar51
进行中（未招募）
1 期
Phase II Trial of Plitidepsin (Aplidin®) in Combination with Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to bortezomib and lenalidomide .Multiple Myeloma Double Refractory.MedDRA version: 19.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2015-003486-29-FRPharma Mar, S.A.64
进行中（未招募）
1 期
Phase II Trial of Plitidepsin (Aplidin®) in Combination with Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to bortezomib and lenalidomide .EUCTR2015-003486-29-ESPharma Mar, S.A.64
终止
2 期
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and LenalidomideMultiple MyelomaNCT03117361PharmaMar10